Zhi Cheng

5PUBLICATIONS
14CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 13, 2024
A 5-Year Follow-up Clinical Study of the B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma.

Dongjian Chen, Yu Zhu, Zhi Chen

|Dec 15, 2023
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously.

Qingming Wang, Runhong Wei, Shufang Guo

|Oct 05, 2022
Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.

Dongjian Chen, Xiaoxiang Wang, Zhi Chen

|Apr 30, 2022
CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status.

Juan Du, Runhong Wei, Songfu Jiang

|May 18, 2021
Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature.

Guoxing Zhao, Runhong Wei, Lei Feng

Pageof 1

Frequent Collaborators

3 joint publications

Juan Du

1 joint publications

Dongjian Chen

1 joint publications

Yu Zhu

1 joint publications

Songfu Jiang